Marshall Wace’s Varian Medical Systems, Inc. VAR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-59,667
Closed -$10.5M 3517
2021
Q1
$10.5M Sell
59,667
-221,169
-79% -$38.9M 0.05% 423
2020
Q4
$49.1M Buy
280,836
+178,643
+175% +$31M 0.27% 77
2020
Q3
$17.6M Buy
102,193
+66,601
+187% +$10.5M 0.11% 184
2020
Q2
$4.36M Sell
35,592
-59,773
-63% -$6.92M 0.03% 520
2020
Q1
$9.79M Sell
95,365
-6,503
-6% -$859K 0.1% 216
2019
Q4
$14.5M Sell
101,868
-58,548
-36% -$7.47M 0.1% 232
2019
Q3
$19.1M Sell
160,416
-62,765
-28% -$7.47M 0.15% 161
2019
Q2
$30.4M Sell
223,181
-3,221
-1% -$430K 0.25% 81
2019
Q1
$32.1M Buy
226,402
+103,501
+84% +$13.6M 0.3% 60
2018
Q4
$13.9M Sell
122,901
-59,462
-33% -$6.8M 0.14% 178
2018
Q3
$20.4M Sell
182,363
-29,879
-14% -$3.38M 0.17% 161
2018
Q2
$24.1M Buy
+212,242
New +$25.4M 0.36% 81
2017
Q1
Sell
-22,813
Closed -$1.8M 864
2016
Q4
$1.8M Buy
+22,813
New +$1.85M 0.01% 660
2014
Q4
Sell
-6,057
Closed -$426K 1038
2014
Q3
$426K Buy
6,057
+2,314
+62% +$171K 0.01% 659
2014
Q2
$273K Buy
+3,743
New +$269K ﹤0.01% 776

Other funds holding VAR

Marshall Wace's VAR Position: Q2 2021 in Review

Marshall Wace sold out of Varian Medical Systems, Inc. (VAR) in Q2 2021, closing a stake of 59,667 shares — an estimated $10.5M sold.

Marshall Wace first reported a position in VAR in Q2 2014 and held it in 15 quarters. The position peaked at $49.1M in Q4 2020. 1 fund tracked by Wall St. Rank holds VAR as of Q2 2021.

  • Marshall Wace reported no remaining Varian Medical Systems, Inc. position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace sold 59,667 Varian Medical Systems, Inc. shares in Q2 2021, an estimated $10.5M.
  • Marshall Wace first reported a position in Varian Medical Systems, Inc. in Q2 2014 and held it in 15 quarters.
  • Marshall Wace's Varian Medical Systems, Inc. position peaked at $49.1M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Varian Medical Systems, Inc. as of Q2 2021.

Based on Marshall Wace's 13F filing for Q2 2021, filed 13 Aug 2021.